Impact of Coronary Artery Disease and Percutaneous Coronary Intervention on Transcatheter Aortic Valve Implantation
Table 4
Baseline characteristics of PCI subgroup in CAD-TAVI population.
CAD group
PCI group
No PCI group
value PCI versus no PCI
N = 372
N = 255
N = 117
Age
84 ± 7
84 ± 6.7
84 ± 7.5
0.21
Male
196 (52.7)
132 (52.2)
64 (53.8)
0.77
Hypertension
253 (68)
172 (68)
81 (68.1)
0.98
Diabetes mellitus
108 (29)
77 (30.4)
31 (26.1)
0.38
Dyslipidemia
175 (47)
124 (49)
51 (42.9)
0.26
Smoking
6 (1.6)
1 (0.4)
5 (4.2)
0.007
BMI
26.2 ± 4.9
26.2 ± 4.8
26.1 ± 5.1
0.57
Chronic respiratory disease
61 (16.4)
36 (14.2)
25 (21)
0.1
Atrial fibrillation
130 (34.9)
81 (32)
49 (41.2)
0.08
Prior stroke
41 (11)
29 (11.5)
12 (10.1)
0.69
Prior PAD
31 (8.3)
17 (6.7)
14 (11.8)
0.1
EuroScore1
14.3 ± 10
14.1 ± 10.2
14.6 ± 9.2
0.57
STS-PROM
6.3 ± 4.7
6.6 ± 4.9
5.8 ± 4.3
0.24
Baseline LVEF
53.2 ± 12.3
53.9 ± 11.6
53.4 ± 12.1
0.8
Antithrombotic treatment
None
35 (9.4)
11 (4.3)
24 (20.2)
<0.001
Single-antiplatelet therapy
65 (17.5)
23 (9.1)
42 (35.3)
Dual-antiplatelet therapy
156 (41.9)
151 (59.7)
5 (4.2)
Anticoagulation therapy
49 (13.2)
6 (2.4)
43 (36.1)
Antiplatelet + anticoagulation
67 (18)
62 (24.5)
5 (4.2)
TAVI approach
Transfemoral
349 (93.8)
237 (93.7))
112 (94.1)
0.9
Transaortic
18 (4.8)
12 (4.7)
6 (5)
Transsubclavian
0 (0)
3 (1.2)
1 (0.8)
Transcarotid
4 (1.1)
1 (0.4)
0 (0)
1 (0.3)
Valve in valve
14 (3.8)
9 (3.6)
5 (4.2)
0.76
Prosthesis type
Ballon expandable
217 (58.3)
151 (59.7)
66 (55.5)
0.44
Self-expanding
155 (41.7)
102 (40.3)
53 (44.5)
Post-TAVI LVEF
54.7 ± 10.7
54.9 ± 10.6
54.8 ± 10.9
0.9
CAD = coronary artery disease. PCI = percutaneous coronary intervention. BMI = body mass index. PAD = peripheral artery disease. EuroScore = European System for Cardiac Operative Risk Evaluation. STS-PROM=Society of Thoracic Surgeons Predicted Risk of Mortality. TAVI = transcatheter aortic valve implantation. CCU = cardiac care unit.
